Last reviewed · How we verify
NCT06637007
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Phase 2 trial testing Chidamide Tablets combined with AK112 in Sarcoma,Soft Tissue in 30 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Shanxi Province Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 August 2024 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chidamide Tablets combined with AK112 — full drug profile →
Conditions studied
- Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →
- Sarcoma — all drugs for Sarcoma →
- Sarcoma of Bone — all drugs for Sarcoma of Bone →
Sponsor
Shanxi Province Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Sarcoma,Soft Tissue or Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06637007
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma,Soft Tissue
Currently open trials in the same condition.
- NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
- NCT07066982 — Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas · Phase 1, PHASE2 · recruiting
- NCT06660810 — Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · Phase 2 · active not recruiting
- NCT05813327 — Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma · Phase 1 · active not recruiting
- NCT06408441 — The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN) · recruiting
Other Shanxi Province Cancer Hospital trials
Trials by the same sponsor.
- NCT07486648 — Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib · Phase 1, PHASE2 · not yet recruiting
- NCT07489339 — MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy · NA · completed
- NCT06319404 — Immune Function of Colorectal Cancer Lymph Nodes · unknown
- NCT06255704 — A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Ma · Phase 2 · not yet recruiting
- NCT07490639 — Family-Supported Palliative Care in Advanced Lung Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06637007 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Province Cancer Hospital
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06637007.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing